PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 193 filers reported holding PDL BIOPHARMA INC in Q4 2016. The put-call ratio across all filers is 0.18 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $581,000 | -47.8% | 273,850 | -17.6% | 0.00% | -100.0% |
| Q3 2016 | $1,112,000 | +12.0% | 332,209 | +5.0% | 0.00% | 0.0% |
| Q2 2016 | $993,000 | +102.7% | 316,369 | +114.8% | 0.00% | – |
| Q1 2016 | $490,000 | -44.6% | 147,280 | -41.1% | 0.00% | – |
| Q4 2015 | $885,000 | -53.4% | 250,103 | -33.8% | 0.00% | -100.0% |
| Q3 2015 | $1,901,000 | -14.7% | 377,789 | +9.0% | 0.00% | 0.0% |
| Q2 2015 | $2,229,000 | +0.6% | 346,730 | +10.2% | 0.00% | 0.0% |
| Q1 2015 | $2,215,000 | +8.8% | 314,737 | +19.3% | 0.00% | 0.0% |
| Q4 2014 | $2,035,000 | -11.4% | 263,767 | -14.2% | 0.00% | 0.0% |
| Q3 2014 | $2,297,000 | -21.0% | 307,450 | +2.3% | 0.00% | -50.0% |
| Q2 2014 | $2,909,000 | +58.3% | 300,502 | +35.9% | 0.00% | +100.0% |
| Q1 2014 | $1,838,000 | +7.9% | 221,111 | +9.6% | 0.00% | 0.0% |
| Q4 2013 | $1,703,000 | -3.7% | 201,762 | -9.0% | 0.00% | 0.0% |
| Q3 2013 | $1,768,000 | +13.6% | 221,646 | +10.0% | 0.00% | 0.0% |
| Q2 2013 | $1,557,000 | – | 201,555 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
| Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
| GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
| Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
| Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
| Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
| RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
| SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |